Search results
Results from the WOW.Com Content Network
This page was last edited on 3 February 2024, at 22:53 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
However, Ceribell’s IPO in 2024 suggests there could be room for transformative companies to go public in the coming years.” — Vijay Rajasekhar, associate, Intuitive Ventures
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The IPO market finally loosened up in late 2023 after one of the worst periods for debuts in more than a decade. Rapidly rising interest rates – courtesy of an aggressive Federal Reserve ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Need help? Call us! 800-290-4726 Login / Join. Mail